VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C

被引：0
|
作者：
Hammond, E. [1 ]
Lucas, A. [1 ]
Lucas, M. [1 ]
Phillips, E. [1 ,4 ,5 ]
Gaudieri, S. [2 ,3 ,6 ,7 ]
机构：
[1] Murdoch Univ, Inst Immunol & Infect Dis, Ctr Clin Immunol & Biomed Stat, Murdoch, WA 6150, Australia
[2] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
[4] Univ Western Australia, Sch Pathol, Nedlands, WA 6009, Australia
[5] Univ Western Australia, Lab Med & Biomed Biomol & Chem Sci, Nedlands, WA 6009, Australia
[6] Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia
[7] Univ Western Australia, Ctr Forens Sci, Nedlands, WA 6009, Australia
来源：
DRUGS OF THE FUTURE | 2010年 / 35卷 / 10期
关键词：
MK-7009; CHRONIC HEPATITIS-C; VIRUS NS3/4A PROTEASE; PEGINTERFERON ALPHA-2A; RIBAVIRIN THERAPY; RESISTANCE; INHIBITORS; TELAPREVIR; NOMENCLATURE; ASSOCIATION; MANAGEMENT;
D O I：
10.1358/dof.2010.035.010.1527293
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protease inhibitors are among a number of new classes of direct-acting antivirals for hepatitis C which, when combined with conventional peginterferon alfa/ribavirin or with other classes of direct-acting antivirals, offer the potential to vastly improve disease outcomes for affected individuals. Early evaluations imply that a number of these agents are well tolerated and produce encouraging rapid declines in plasma viral load. Concerns relate to the rapid development of drug resistance, with resulting viral rebound. Vaniprevir (MK-7009) is a novel inhibitor of genotype 1 proteases with some potency against genotype 2 currently undergoing phase II trials.
引用
收藏
页码：803 / 813
页数：11
相关论文
共 50 条
  • [31] NS3•4A protease as a target for interfering with hepatitis C virus replication
    Perni, RB
    DRUG NEWS & PERSPECTIVES, 2000, 13 (02) : 69 - 77
  • [32] Inhibition of the hepatitis C virus NS3/4A protease - The crystal structures of two protease-inhibitor complexes
    Di Marco, S
    Rizzi, M
    Volpari, C
    Walsh, MA
    Narjes, F
    Colarusso, S
    De Francesco, R
    Matassa, VG
    Sollazzo, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (10) : 7152 - 7157
  • [33] Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection
    Deutsch, Melanie
    Papatheodoridis, George V.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (08) : 951 - 963
  • [34] Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
    Rosenquist, Asa
    Samuelsson, Bertil
    Johansson, Per-Ola
    Cummings, Maxwell D.
    Lenz, Oliver
    Raboisson, Pierre
    Simmen, Kenny
    Vendeville, Sandrine
    de Kock, Herman
    Nilsson, Magnus
    Horvath, Andras
    Kalmeijer, Ronald
    de la Rosa, Guy
    Beumont-Mauviel, Maria
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1673 - 1693
  • [35] Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
    Soumana, Djade I.
    Ali, Akbar
    Schiffer, Celia A.
    ACS CHEMICAL BIOLOGY, 2014, 9 (11) : 2485 - 2490
  • [36] Boceprevir, an NS3 Protease Inhibitor of HCV
    Berman, Kenneth
    Kwo, Paul Y.
    CLINICS IN LIVER DISEASE, 2009, 13 (03) : 429 - +
  • [37] Discovery of a second generation, pan genotype NS3/4A protease inhibitor (BMS-986144) for the treatment of hepatitis C
    Scola, Paul
    Sun, Li-Qiang
    Gillis, Eric
    Bowsher, Michael
    Chen, Jie
    Wang, Xiangdong
    Sit, Sing-Yueng
    Chen, Yan
    Zheng, Zhizhen
    D'Andrea, Stanley
    Sin, Ny
    Venables, Brian
    Mull, Eric
    Chen, Qian
    Kandhasamy, Sarkunam
    Pulicharla, Nagalakshmi
    Vishwakrishnan, Sureshbabu
    Reddy, Subba
    Trivedi, Ravi
    Sinha, Sarmistha
    Sivaprasad, Sankar
    Rao, Abhijith
    Desai, Salil
    Ghosh, Kaushik
    Rajamani, Ramkumar
    Friborg, Jacques
    Levine, Steven
    Chen, Chaoqun
    Falk, Paul
    Jenkins, Susan
    Kramer, Melissa
    Haskel, Roy
    Johnson, Kimberly
    Loy, James
    Levesque, Paul
    Zhu, Jia
    Cockett, Mark
    Meanwell, Nicholas
    McPhee, Fiona
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [38] GRAZOPREVIR POTASSIUM HCV NS3 NS4A protease inhibitor Anti-hepatitis C virus drug
    Majumdar, A.
    Gilliam, B. L.
    DRUGS OF THE FUTURE, 2016, 41 (02) : 85 - 109
  • [39] In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
    Lenz, Oliver
    Verbinnen, Thierry
    Lin, Tse-I
    Vijgen, Leen
    Cummings, Maxwell D.
    Lindberg, Jimmy
    Berke, Jan Martin
    Dehertogh, Pascale
    Fransen, Els
    Scholliers, Annick
    Vermeiren, Katrien
    Ivens, Tania
    Raboisson, Pierre
    Edlund, Michael
    Storm, Susan
    Vrang, Lotta
    de Kock, Herman
    Fanning, Gregory C.
    Simmen, Kenneth A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 1878 - 1887
  • [40] Boceprevir. NS3 protease inhibitor, Treatment of chronic hepatitis C
    Campas, C.
    Pandian, R.
    Bolos, J.
    Castaner, R.
    DRUGS OF THE FUTURE, 2009, 34 (09) : 697 - 707
12345